Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.610
-0.020 (-1.23%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.

The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease.

It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer.

In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).

Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications.

The company is based in New York, New York.

Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals logo
CountryUnited States
Founded2000
IndustryBiotechnology
SectorHealthcare
Employees37
CEOSandesh Seth

Contact Details

Address:
100 Park Avenue, 23rd Floor
New York, New York 10017
United States
Phone646 677 3870
Websiteactiniumpharma.com

Stock Details

Ticker SymbolATNM
ExchangeNYSEAMERICAN
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001388320
CUSIP Number00507W107
ISIN NumberUS00507W2061
Employer ID88-0378336
SIC Code2834

Key Executives

NamePosition
Sandesh C. Seth M.B.A., M.S.Chairman and Chief Executive Officer
Steven O'Loughlin BSChief Financial Officer and Corporate Secretary
Dr. Paul Diamond Esq., Ph.D.Vice President of Patent and Legal Counsel
Dr. Avinash Desai M.D.Chief Medical Officer
Jenny HsiehChief Strategy Officer
Caroline YarbroughChief Commercial Officer
Lynn M. Bodarky M.B.A.Chief Business Officer
J. C. SimeonExecutive Director of Quality Assurance
Dr. Madhuri Vusirikala M.D.Vice President of Clinical Development BMT and Cellular Therapy

Latest SEC Filings

DateTypeTitle
Jul 29, 2025SCHEDULE 13G/AFiling
Jul 16, 2025SCHEDULE 13G/AFiling
May 9, 202510-QQuarterly Report
May 9, 20258-KCurrent Report
Mar 31, 202510-KAnnual Report
Nov 27, 20248-KCurrent Report
Nov 14, 202410-QQuarterly Report
Nov 12, 2024SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024ARSFiling